Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 20Carcinoma, Renal Cell 10Neuroendocrine Tumors 7Neoplasm Metastasis 7Recurrence 4Tuberous Sclerosis 3Triple Negative Breast Neoplasms 3Neoplasms 3Kidney Neoplasms 3Endometrial Neoplasms 3von Hippel-Lindau Disease 2Skin Neoplasms 2Sarcoma 2Meningioma 2Glioma 2Gastro-enteropancreatic neuroendocrine tumor 2Diffuse Intrinsic Pontine Glioma 2Carcinoma, Hepatocellular 2Adenoma, Islet Cell 2Waldenstrom Macroglobulinemia 1Vascular Malformations 1Unilateral Breast Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Diseases 1Thymus Neoplasms 1Seizures 1Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1

Interventions

trametinib 1spartalizumab 1pembrolizumab 1lenvatinib 1gallium Ga 68 dotatate 1dabrafenib 1Sorafenib 1Sodium Iodide 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid cancer, Hurthle cell × Everolimus × 1 year × Clear all
NCT02143726 2026-02-11

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
35 enrolled 14 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡